BE2010C011I2 - - Google Patents

Info

Publication number
BE2010C011I2
BE2010C011I2 BE2010C011C BE2010C011C BE2010C011I2 BE 2010C011 I2 BE2010C011 I2 BE 2010C011I2 BE 2010C011 C BE2010C011 C BE 2010C011C BE 2010C011 C BE2010C011 C BE 2010C011C BE 2010C011 I2 BE2010C011 I2 BE 2010C011I2
Authority
BE
Belgium
Application number
BE2010C011C
Other languages
French (fr)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10854788&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2010C011(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BE2010C011I2 publication Critical patent/BE2010C011I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/74—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C215/76—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring
    • C07C215/80—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton of the same non-condensed six-membered aromatic ring containing at least two amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE2010C011C 1999-06-04 2010-02-24 BE2010C011I2 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9913083.3A GB9913083D0 (en) 1999-06-04 1999-06-04 Organic compounds

Publications (1)

Publication Number Publication Date
BE2010C011I2 true BE2010C011I2 (et) 2019-05-21

Family

ID=10854788

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2010C011C BE2010C011I2 (et) 1999-06-04 2010-02-24

Country Status (38)

Country Link
US (9) US6878721B1 (et)
EP (2) EP2332915B1 (et)
JP (1) JP3785365B2 (et)
KR (1) KR100718615B1 (et)
CN (1) CN1156451C (et)
AR (1) AR035548A1 (et)
AT (1) ATE440083T1 (et)
AU (1) AU765919B2 (et)
BE (1) BE2010C011I2 (et)
BR (1) BRPI0011324B8 (et)
CA (1) CA2375810C (et)
CO (1) CO5170518A1 (et)
CY (3) CY1109604T1 (et)
CZ (1) CZ302403B6 (et)
DE (2) DE60042781D1 (et)
DK (2) DK1183240T3 (et)
ES (2) ES2402535T3 (et)
FR (1) FR10C0006I2 (et)
GB (1) GB9913083D0 (et)
HK (2) HK1045837B (et)
HU (1) HU227034B1 (et)
IL (2) IL146578A0 (et)
LU (1) LU91651I2 (et)
MX (1) MXPA01012474A (et)
MY (1) MY126951A (et)
NL (1) NL300437I1 (et)
NO (2) NO322944B1 (et)
NZ (1) NZ515669A (et)
PE (1) PE20010219A1 (et)
PL (1) PL198847B1 (et)
PT (2) PT2332915E (et)
RU (1) RU2244709C2 (et)
SI (1) SI1183240T1 (et)
SK (1) SK287260B6 (et)
TR (1) TR200103497T2 (et)
TW (1) TWI253447B (et)
WO (1) WO2000075114A1 (et)
ZA (1) ZA200109931B (et)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
TWI243164B (en) 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
GB0121214D0 (en) * 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
EP2311818B1 (en) 2002-02-28 2013-01-16 Novartis AG Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug
US6933410B2 (en) * 2002-03-08 2005-08-23 Novartis Ag Process for preparing 5,6-diethyl-2,3-dihydro-1H-inden-2-amine
DE10256080A1 (de) * 2002-11-29 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tiotropiumhaltige Arzneimittelkombination für die Inhalation
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
TWI324151B (en) * 2003-04-02 2010-05-01 Novartis Ag Process for the preparation of 5-(haloacetyl)-8-substituted oxy-(1h)-quinolin-2-ones
GB0307856D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
PT1613315E (pt) * 2003-04-04 2009-04-22 Novartis Ag Derivados da quinolina-2-ona para o tratamento de doenças das vias aéreas respiratórias
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
EP1574501A1 (en) * 2004-03-11 2005-09-14 Pfizer Limited Quinolinone derivatives, pharmaceutical compositions containing them and their use
WO2005092861A1 (en) * 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
KR20120091378A (ko) 2004-03-23 2012-08-17 노파르티스 아게 제약 조성물
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds
WO2006031556A2 (en) * 2004-09-10 2006-03-23 Theravance. Inc. Amidine substituted aryl aniline compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0511066D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0511065D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
WO2007024183A1 (en) * 2005-08-26 2007-03-01 Astrazeneca Ab A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
AR058104A1 (es) 2005-10-21 2008-01-23 Novartis Ag Compuestos organicos
TWI392493B (zh) * 2005-10-26 2013-04-11 Novartis Ag 格隆溴銨(GLYCOPYRROLATE)及β2腎上腺素受體激動劑之組合
GB0525671D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
JP5373599B2 (ja) 2006-04-21 2013-12-18 ノバルティス アーゲー アデノシンａ２ａ受容体アゴニストとして使用するためのプリン誘導体
EP1878722A1 (en) * 2006-07-13 2008-01-16 Novartis AG Quinolinone derivatives and their pharmaceutical compositions
CN101479245B (zh) * 2006-06-30 2013-05-22 诺瓦提斯公司 喹啉酮衍生物和其药物组合物
EP1914227A1 (en) * 2006-08-31 2008-04-23 Novartis AG Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としてのピラゾロピリミジン
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
BRPI0720799A2 (pt) 2007-01-10 2014-03-11 Irm Llc Compostos e composições como inibidores de protease de ativação de canal.
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
EA200901082A1 (ru) 2007-02-09 2010-02-26 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
AU2008248598B2 (en) 2007-05-07 2011-11-17 Novartis Ag Organic compounds
CA2707857C (en) 2007-12-10 2016-09-13 Novartis Ag Spirocyclic amiloride analogues
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
KR20110040818A (ko) 2008-06-10 2011-04-20 노파르티스 아게 상피 나트륨 채널 차단제로서의 피라진 유도체
CA2726746A1 (en) 2008-06-18 2009-12-23 Astrazeneca Ab Benzoxazinone derivatives acting as beta2-adrenoreceptor agonist for the treatment of respiratory disorders
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
DK2379507T3 (da) 2008-12-30 2014-01-27 Pulmagen Therapeutics Inflammation Ltd Sulfonamidforbindelser til behandling af åndedrætsforstyrrelser
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
TW201040154A (en) * 2009-02-13 2010-11-16 Sanofi Aventis Novel substituted indanes, process for preparation thereof and use thereof as a medicament
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
MX2012001838A (es) 2009-08-12 2012-02-29 Novartis Ag Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
CA2771532C (en) 2009-08-17 2021-03-23 Intellikine, Inc. Heterocyclic compounds and uses thereof
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
AU2010310449A1 (en) 2009-10-22 2012-05-03 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011056929A1 (en) * 2009-11-04 2011-05-12 Massachusetts Institute Of Technology Continuous flow synthesis of amino alcohols using microreactors
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
JP2013520414A (ja) * 2010-02-18 2013-06-06 アストラゼネカ・アクチエボラーグ シクロプロピルベンズアミド誘導体の新規な結晶形態
WO2011109276A1 (en) 2010-03-01 2011-09-09 Massachussets Institute Of Technology Epoxidation catalysts
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
CN103097385B (zh) 2010-07-14 2016-08-03 诺华股份有限公司 Ip受体激动剂杂环化合物
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
CN107998109A (zh) 2010-10-12 2018-05-08 西普拉有限公司 药物组合物
JOP20120023B1 (ar) 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
WO2012107500A1 (en) 2011-02-10 2012-08-16 Novartis Ag [1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
GEP20156285B (en) 2011-02-25 2015-05-11 Aierem Elelsi Compounds and compositions as trk inhibitors
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
WO2013038390A1 (en) 2011-09-16 2013-03-21 Novartis Ag N-substituted heterocyclyl carboxamides
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
EP2802581A1 (en) 2012-01-13 2014-11-19 Novartis AG 7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802585A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
TW201335160A (zh) 2012-01-13 2013-09-01 Novartis Ag Ｉｐ受體激動劑之雜環化合物
WO2013105063A1 (en) 2012-01-13 2013-07-18 Novartis Ag Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
EP2802582A1 (en) 2012-01-13 2014-11-19 Novartis AG Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
US9174985B2 (en) 2012-01-13 2015-11-03 Novartis Ag Salts of 7-(2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid as IP receptor agonists
WO2013132514A2 (en) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
WO2014008640A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
WO2014008639A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 制备茚达特罗的方法
CN103539677B (zh) * 2012-07-16 2015-04-22 武汉万知生物医药有限公司 一种5,6-二乙基-2,3-二氢-1h-茚-2-胺盐酸盐的制备方法
WO2014044288A1 (en) 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
EP3848354B1 (en) 2012-09-21 2022-07-27 Crystal Pharma, S.A.U. Process for the preparation of indacaterol and intermediates thereof
MX2015007936A (es) 2012-12-19 2016-03-11 Novartis Ag Inhibidores de autotaxina.
WO2014108449A1 (en) 2013-01-08 2014-07-17 Atrogi Ab A screening method, a kit, a method of treatment and a compound for use in a method of treatment
CN105189500A (zh) 2013-02-13 2015-12-23 诺华股份有限公司 Ip受体激动剂杂环化合物
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
MX2015012529A (es) 2013-03-14 2016-07-05 Novartis Ag Deamorfizacion de formulaciones secadas por pulverizacion a traves de pulverizacion de la mezcla.
US9452139B2 (en) 2013-03-14 2016-09-27 Novartis Ag Respirable agglomerates of porous carrier particles and micronized drug
JP2016512835A (ja) 2013-03-15 2016-05-09 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせ及びそれらの使用
CZ306252B6 (cs) 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
ES2626829T3 (es) * 2013-03-27 2017-07-26 Laboratorios Lesvi, S.L. Procedimiento para la fabricación de (R)-5[2-(5,6-dietil-indan-2-ilamino)-1-hidroxietil]-8-hidroxi-(1H)-quinolin-2-ona
WO2015008229A1 (en) 2013-07-18 2015-01-22 Novartis Ag Autotaxin inhibitors
BR112016000779A8 (pt) 2013-07-18 2020-01-07 Novartis Ag inibidores de autotaxina que compreendem núcleo do ciclo de benzilamida de anel heteroaromático, seus usos, composição e combinação farmacêuticas
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
CN104744360B (zh) * 2013-12-26 2017-02-22 成都伊诺达博医药科技有限公司 一种合成茚达特罗的新方法
PT3092217T (pt) 2014-01-09 2020-09-04 Ramamohan Rao Davuluri Processo inovador para preparação de indacaterol ou dos seus sais farmaceuticamente aceitáveis
CN103830193A (zh) * 2014-03-11 2014-06-04 熊妲妮 茚达特罗片制剂及其制备方法
CN103830195A (zh) * 2014-03-11 2014-06-04 熊妲妮 一种茚达特罗片及其制备方法
CN106102724A (zh) 2014-03-27 2016-11-09 诺华股份有限公司 用于吸入活性药物成分的经喷雾干燥的水包油包固体分散系
EP3134398A1 (en) 2014-04-24 2017-03-01 Novartis Ag Autotaxin inhibitors
BR112016023967A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
EP3134397A1 (en) 2014-04-24 2017-03-01 Novartis AG Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
JP6454727B2 (ja) 2014-04-24 2019-01-16 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピリジン誘導体
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
EP3174869B1 (en) 2014-07-31 2020-08-19 Novartis AG Combination therapy of a met inhibitor and an egfr inhibitor
DE102014217201A1 (de) 2014-08-28 2016-03-03 Henkel Ag & Co. Kgaa Verwendung einer Kombination von Rheolate FX 1100 und Luviskol K90
DE102014217205A1 (de) 2014-08-28 2016-03-03 Henkel Ag & Co. Kgaa Verwendung einer Kombination von Rheolate FX 1100 und Luviskol VA 64 W
AU2016209930A1 (en) 2015-01-20 2017-07-13 Novartis Ag Application unlock using a connected physical device and transfer of data therebetween
EP3247693B1 (en) * 2015-01-20 2019-09-04 OLON S.p.A. Process for the preparation of indanamine derivatives and new synthesis intermediates
CN107531636B (zh) * 2015-04-09 2022-11-25 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
ES2897697T3 (es) 2015-07-03 2022-03-02 Novartis Ag Inhalador adaptado para leer información almacenada en un medio de almacenamiento de datos de un recipiente
ITUB20153978A1 (it) * 2015-09-28 2017-03-28 Laboratorio Chimico Int S P A Procedimento per la preparazione di derivati di indanammina e di nuovi intermedi di sintesi.
CN105884626B (zh) * 2016-05-04 2017-10-20 龙曦宁（上海）医药科技有限公司 一种2‑氨基茚满衍生物的合成方法及其产品
CN108101841B (zh) * 2016-11-24 2021-04-06 江苏恒瑞医药股份有限公司 一种制备茚达特罗或其盐的方法
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
EP3735406B1 (en) 2018-01-02 2022-05-11 Deva Holding Anonim Sirketi A process for preparation of 5-(2-(substituted-amino)-1-hydroxyethyl)-8-(substituted-oxy) quinolin-2(1h)-one
KR20200133349A (ko) 2018-03-19 2020-11-27 다우 글로벌 테크놀로지스 엘엘씨 폴리올레핀 - 폴리디오르가노실록산 블록 공중합체 및 이의 합성을 위한 히드로실릴화 반응 방법
US11814555B2 (en) 2018-03-19 2023-11-14 Dow Silicones Corporation Hot melt adhesive compositions containing polyolefin-polydiorganosiloxane copolymers and methods for the preparation and use thereof
EP3768792B1 (en) 2018-03-19 2023-09-20 Dow Silicones Corporation Hot melt adhesive composition containing a polyolefin - polydiorganosiloxane copolymer and methods for the preparation and use thereof
JP7334195B2 (ja) 2018-07-17 2023-08-28 ダウ シリコーンズ コーポレーション ポリシロキサン樹脂－ポリオレフィンコポリマー並びにその調製方法及び使用方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
WO2020081257A1 (en) 2018-10-05 2020-04-23 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CN109369417B (zh) * 2018-10-19 2021-07-06 诚达药业股份有限公司 一种2-氨基茚满衍生物的制备方法
WO2020105012A1 (en) 2018-11-22 2020-05-28 Glenmark Specialty S.A. Sterile compositions of indacaterol suitable for nebulization
US20200215051A1 (en) 2019-01-03 2020-07-09 Glenmark Specialty S.A. Nebulization composition comprising tiotropium and indacaterol
CN109896967B (zh) * 2019-04-04 2021-10-22 上海工程技术大学 一种间二乙氨基苯酚的制备方法
CN109896966B (zh) * 2019-04-04 2021-10-22 上海工程技术大学 一种n,n-二丁基间氨基苯酚的制备方法
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
CN110229078A (zh) * 2019-05-22 2019-09-13 博诺康源(北京)药业科技有限公司 一种茚达特罗起始原料开环杂质的制备
BR112021024668A2 (pt) 2019-06-10 2022-05-31 Novartis Ag Derivado de piridina e pirazina para o tratamento de fc, dpoc e bronquiectasia
JOP20220044A1 (ar) 2019-08-28 2023-01-30 Novartis Ag مشتقات 1، 3- فينيل أريل غير متجانسة بها استبدال واستخدامها في معالجة مرض
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
EP4126819A1 (en) * 2020-04-03 2023-02-08 Vertex Pharmaceuticals Incorporated 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
JP2023537357A (ja) 2020-08-14 2023-08-31 ノバルティス アーゲー ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用
US11844793B2 (en) 2020-09-29 2023-12-19 Aerorx Therapeutics Llc Liquid formulations of indacaterol
CN115677577A (zh) * 2021-11-03 2023-02-03 中国药科大学 靶向srsf6蛋白的小分子化合物及其制备方法和用途
GB202205895D0 (en) 2022-04-22 2022-06-08 Atrogi Ab New medical uses

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8707123D0 (en) 1987-03-25 1987-04-29 Pfizer Ltd Antiarrhythmic agents
AU632809B2 (en) 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
ZA903906B (en) * 1989-05-25 1992-02-26 Takeda Chemical Industries Ltd Benzocycloalkane derivatives and production thereof
GB9107827D0 (en) 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
JPH0518007A (ja) 1991-07-05 1993-01-26 Konoike Constr Ltd 鉄骨梁との接合部を内蔵したｐｃ柱
IL104567A (en) 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
WO1993018007A1 (en) * 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Novel carbostyril derivative
ES2115003T3 (es) 1993-01-29 1998-06-16 American Cyanamid Co Aminocicloalcanobenzodioxoles como agentes adrenergicos selectivos beta-3.
DK0712387T3 (da) 1993-08-06 2000-05-29 Upjohn Co 2-Aminoindaner som selektive dopamin-D3-ligander
FR2711407B1 (fr) * 1993-10-19 1996-01-26 Allevard Sa Perfectionnements aux barres de torsion métalliques.
US5578638A (en) 1993-11-05 1996-11-26 American Cyanamid Company Treatment of glaucoma and ocular hypertension with β3 -adrenergic agonists
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
KR100427962B1 (ko) 1995-02-01 2004-11-16 파마시아 앤드 업존 캄파니 선택적인도파민디3리간드로서의2-아미노인단
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
TW375604B (en) * 1996-02-19 1999-12-01 Kissei Pharmaceutical 3,4-di-substituting phenyl-ethanolamine-tetrahydronaphthyl carboxylic amide derivatives
JP3708624B2 (ja) * 1996-03-27 2005-10-19 キッセイ薬品工業株式会社 ３，４−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体
JP3690071B2 (ja) 1997-06-24 2005-08-31 井関農機株式会社 ロータリ耕耘具の防護装置
WO1999009001A1 (fr) * 1997-08-19 1999-02-25 Kissei Pharmaceutical Co., Ltd. Derives de phenylethanolaminotetraline et bronchodilatateurs
JP2002512639A (ja) * 1998-04-06 2002-04-23 藤沢薬品工業株式会社 プロパノールアミン誘導体
AU6610001A (en) 2000-06-27 2002-01-08 S A L V A T Lab Sa Carbamates derived from arylalkylamines

Also Published As

Publication number Publication date
SK17432001A3 (sk) 2002-06-04
US7622483B2 (en) 2009-11-24
US7820694B2 (en) 2010-10-26
NO322944B1 (no) 2006-12-18
PL198847B1 (pl) 2008-07-31
LU91651I9 (et) 2019-01-03
US9040559B2 (en) 2015-05-26
HK1045837A1 (en) 2002-12-13
US8067437B2 (en) 2011-11-29
FR10C0006I2 (fr) 2011-04-01
DE122010000009I2 (de) 2012-08-09
PT2332915E (pt) 2013-04-11
CY1109604T1 (el) 2012-01-25
DE122010000009I1 (de) 2010-07-01
TWI253447B (en) 2006-04-21
PL352100A1 (en) 2003-07-28
ES2331457T3 (es) 2010-01-05
HUP0201658A3 (en) 2005-01-28
AU5074500A (en) 2000-12-28
US8658673B2 (en) 2014-02-25
CY2010003I1 (el) 2012-01-25
DE60042781D1 (de) 2009-10-01
WO2000075114A1 (en) 2000-12-14
IL146578A (en) 2007-05-15
CZ302403B6 (cs) 2011-05-04
US20050153957A1 (en) 2005-07-14
CN1353692A (zh) 2002-06-12
CY1114120T1 (el) 2016-07-27
NL300437I1 (nl) 2010-04-01
LU91651I2 (fr) 2010-04-19
JP2003501417A (ja) 2003-01-14
NO2010014I1 (no) 2010-07-26
US20120077838A1 (en) 2012-03-29
US6878721B1 (en) 2005-04-12
US20130231367A1 (en) 2013-09-05
US8436017B2 (en) 2013-05-07
SI1183240T1 (sl) 2010-01-29
FR10C0006I1 (et) 2010-03-26
US8283362B2 (en) 2012-10-09
ES2402535T3 (es) 2013-05-06
TR200103497T2 (tr) 2002-05-21
US20110034509A1 (en) 2011-02-10
NO20015912L (no) 2002-01-21
CA2375810C (en) 2010-09-07
KR100718615B1 (ko) 2007-05-16
NO20015912D0 (no) 2001-12-03
MXPA01012474A (es) 2002-06-04
EP1183240A1 (en) 2002-03-06
HU227034B1 (en) 2010-05-28
GB9913083D0 (en) 1999-08-04
US20120302531A1 (en) 2012-11-29
BRPI0011324B8 (pt) 2021-05-25
US20140343091A1 (en) 2014-11-20
DK2332915T3 (da) 2013-05-27
MY126951A (en) 2006-11-30
HK1154584A1 (en) 2012-04-27
EP2332915B1 (en) 2013-02-27
US8796307B2 (en) 2014-08-05
AU765919B2 (en) 2003-10-02
SK287260B6 (sk) 2010-04-07
CY2010003I2 (el) 2012-01-25
JP3785365B2 (ja) 2006-06-14
BR0011324A (pt) 2002-03-05
HK1045837B (zh) 2010-03-26
NO2010014I2 (et) 2011-10-17
EP2332915A1 (en) 2011-06-15
CN1156451C (zh) 2004-07-07
AR035548A1 (es) 2004-06-16
BR0011324B1 (pt) 2014-11-25
KR20020012590A (ko) 2002-02-16
US20140066478A1 (en) 2014-03-06
EP1183240B1 (en) 2009-08-19
ZA200109931B (en) 2002-06-05
RU2244709C2 (ru) 2005-01-20
PE20010219A1 (es) 2001-03-21
DK1183240T3 (da) 2009-11-23
IL146578A0 (en) 2002-07-25
US20100029705A1 (en) 2010-02-04
CZ20014301A3 (cs) 2002-03-13
CA2375810A1 (en) 2000-12-14
CO5170518A1 (es) 2002-06-27
HUP0201658A2 (en) 2002-08-28
NZ515669A (en) 2004-01-30
ATE440083T1 (de) 2009-09-15
PT1183240E (pt) 2009-11-03

Similar Documents

Publication Publication Date Title
BE2015C057I2 (et)
BE2016C007I2 (et)
BE2014C017I2 (et)
BE2013C051I2 (et)
BE2013C020I2 (et)
BE2013C015I2 (et)
BE2013C001I2 (et)
BE2012C036I2 (et)
BE2011C004I2 (et)
NO2010014I2 (et)
BE2008C046I2 (et)
BE1025464I2 (et)
JP2002529136A5 (et)
BRPI0017527B8 (et)
BE2008C047I2 (et)
JP2002519716A5 (et)
JP2002531762A5 (et)
JP2002532277A5 (et)
JP2002522247A5 (et)
JP2002523877A5 (et)
IN188473B (et)
IN191487B (et)
IN191334B (et)
ECSMU990150U (et)
CN3098953S (et)